Schedule a consultation with us today
The key findings from this clinical program include significant reductions in body weight and fat mass in treatment groups compared to placebo, preferential loss of abdominal and visceral adipose tissue, no changes in serum IGF-1 levels at any dose tested, no negative effects on glucose metabolism or insulin sensitivity, no significant adverse events related to metabolic or endocrine disruption, and safety profile indistinguishable from placebo for most parameters
Traditional doses have been 100mcg
Guide for the Care and Use of Laboratory Animals
Side effect Liraglutide can cause similar GI side effects to semaglutide, including constipation, diarrhea, nausea, and vomiting
The Pharmacist Guide to Assigning a Beyond-Use Date to a Compounded Sterile or Nonsterile Preparation (PDF)